<DOC>
	<DOCNO>NCT00030264</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining methotrexate vinblastine may effective treatment neurofibromatosis type 1 associate progressive plexiform neurofibroma . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient neurofibromatosis type 1 associate progressive plexiform neurofibroma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Neurofibromatosis Progressive Plexiform Neurofibromas</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect chronic vinblastine methotrexate time disease progression child young adult progressive plexiform neurofibroma associate neurofibromatosis type 1 . - Determine objective response rate patient treat regimen . - Determine toxic effect regimen patient . - Determine quality life patient treat regimen . OUTLINE : Patients stratify accord tumor status ( severely debilitate and/or life-threatening v cosmetically disfigure ) . Patients receive methotrexate vinblastine IV weekly 26 week every 2 week 26 week absence disease progression unacceptable toxicity . Quality life assess baseline every 3 month study participation . Patients follow every 3 month disease progression . PROJECTED ACCRUAL : A total 35 patient accrue study within approximately 3 year .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma , Plexiform</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Progressive , debilitating , severely disfigure lifethreatening plexiform neurofibroma ( PN ) surgically resectable standard medical management . Histologic confirmation tumor require presence consistent clinical radiographic finding . However , clinical observation scan suggest possible malignant transformation , tumor must biopsied prior therapy . In addition PN , study subject must least one diagnostic criterion Neurofibromatosis type 1 ( NF1 ) list : 6 caf√©aulait spot &gt; 0.5 cm prepubertal subject &gt; 1.5 cm postpubertal subject freckle axilla groin optic glioma 2 lisch nodule distinctive bony lesion ( dysplasia sphenoid bone dysplasia thin long bone cortex ) first degree relative NF1 2 . Adequate bone marrow , renal , hepatic function : Absolute Neutrophil Count ( ANC ) &gt; 1000 platelet count &gt; 100,000 prior initiation therapy must normal renal function : Blood Urea Nitrogen ( BUN ) /Creatinine &lt; 1.5x normal age ) , alkaline phosphatase ( ALP ) , albumin , total protein bilirubin must normal liver function : Bilirubin , alanine transaminase ( ALT ) , aspartate aminotransferase ( AST ) &lt; 1.5x normal age 3 . Patients must measurable PN direct physical examination ( documented clinical measurement tumor serial photography ) image study . Most patient tumor measure magnetic resonance imaging ( MRI ) , however , patient may cosmetically disfigure PN would best measure clinically serial photography throughout treatment followup . A measurable lesion one whose size quantify least 2 dimension . There must evidence recurrent progressive disease document increase size presence new lesion MRI . Progression define appearance new tumor measurable increase sum product two long perpendicular diameter index lesion ( ) time period &lt; 12 month prior evaluation study . For purpose study , index PN lesion PNs evaluate lifethreatening , debilitate , cosmetically disfigure , and/or easily measure . 4 . Prior therapy : Patients NF1 eligible time recurrence progression inoperable PN . A surgical consultation obtain prior enrollment study evaluate tumor resection feasible option . Patients eligible complete tumor resection feasible patient surgical option refuse surgery . Since standard effective chemotherapy patient NF1 progressive PN , patient may treat trial without receive prior therapy . Patients must recover toxic effect prior therapy enter study . The Cancer Therapy Evaluation Program Common Toxicity Criteria ( CTC ) Version 2.0 use toxicity assessment . Recovery define toxicity grade &lt; 2 , unless otherwise specify Inclusion Exclusion Criteria . Patients must last dose radiation therapy least 6 week prior study entry , last dose chemotherapy least four week prior study entry . Patients receive granulocytecolony stimulate factor ( GCSF ) prior cycle chemotherapy must GCSF least one week prior enter study . 5 . Performance status : Patients life expectancy least 12 month Lansky Karnofsky performance score &gt; 60 . Patients wheelchair bound paralysis consider `` ambulatory '' mobile active wheelchair rather actually ambulatory . 6 . A Pregnancy test must negative female childbearing age . 7 . Informed consent : All patient legal guardian ( patient le 18 year old ) must sign approved document inform consent indicate understanding investigational nature risk study begin therapy . When appropriate pediatric patient include discussion order obtain verbal assent . 1 . Pregnant female exclude 2 . Patient treatment investigational agent within past 30 day . 3 . Ongoing radiation therapy , chemotherapy , hormonal therapy direct tumor immunotherapy . 4 . Inability return followup visit obtain followup study require assess toxicity response therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>plexiform neurofibroma</keyword>
	<keyword>neurofibromatosis type 1</keyword>
</DOC>